| Title |
Canakinumab treatment in renal transplant recipients with familial Mediterranean fever
|
|---|---|
| Published in |
Journal of Nephrology, February 2018
|
| DOI | 10.1007/s40620-018-0475-5 |
| Pubmed ID | |
| Authors |
Tolga Yildirim, Rahmi Yilmaz, Muge Uzerk Kibar, Yunus Erdem |
| Abstract |
Colchicine is the first-line treatment for familial Mediterranean fever (FMF), preventing both inflammatory attacks as well as the development of amyloidosis in the majority of the patients. However approximately 5-10% of patients are colchicine resistant/intolerant. Side effects of colchicine are more prominent in renal transplant recipients due to interaction with immunosuppressive drugs. Anti-interleukin (IL)-1 drugs (anakinra, canakinumab and rilonacept) have emerged as the most promising drugs in the treatment of colchicine-resistant and/or intolerant FMF. There are no existing reports in the literature on canakinumab use in renal transplant recipients with FMF. We report here the efficacy and safety of canakinumab in three renal transplant recipients who achieved a complete clinical response with elimination of attacks and normalization of serum C-reactive protein (CRP) levels without significant side effects. This highlights the advantage of use of this drug in this setting, which has a better tolerability compared to anakinra. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 15% |
| Researcher | 2 | 15% |
| Professor | 1 | 8% |
| Student > Bachelor | 1 | 8% |
| Professor > Associate Professor | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 5 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 31% |
| Biochemistry, Genetics and Molecular Biology | 2 | 15% |
| Social Sciences | 1 | 8% |
| Engineering | 1 | 8% |
| Unknown | 5 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2018.
All research outputs
#19,516,978
of 23,999,200 outputs
Outputs from Journal of Nephrology
#755
of 1,003 outputs
Outputs of similar age
#343,244
of 452,791 outputs
Outputs of similar age from Journal of Nephrology
#10
of 10 outputs
Altmetric has tracked 23,999,200 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,003 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,791 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one.